Clinical leprosy is characterized by varying manifestations between tuberculoid and lepromatous leprosy. In the former state the patient is able to elicit a cell-mediated immune response whereas in the latter, there is usually a humoral response. An understanding of this immunological balance is crucial in the search for a vaccine which will control the disease. The development of a possible anti-Mycobacterium leprae vaccine has been advanced by the isolation of organisms from the infected tissues of the nine-banded armadillo, Dasypus novemcinctus; 125 000 doses can be prepared from one animal. In addition, recent studies on the biochemical activities of these organisms may provide the knowledge required to allow cultivation on a laboratory medium. Eventually it may be possible to produce a combined leprosy:tuberculosis vaccine for use in those parts of the world where both diseases are prevalent.
BT - Vaccine C1 - http://www.ncbi.nlm.nih.gov/pubmed/6397930?dopt=Abstract DA - 1984 Dec DO - 10.1016/0264-410x(84)90037-9 IS - 4 J2 - Vaccine LA - eng N2 -Clinical leprosy is characterized by varying manifestations between tuberculoid and lepromatous leprosy. In the former state the patient is able to elicit a cell-mediated immune response whereas in the latter, there is usually a humoral response. An understanding of this immunological balance is crucial in the search for a vaccine which will control the disease. The development of a possible anti-Mycobacterium leprae vaccine has been advanced by the isolation of organisms from the infected tissues of the nine-banded armadillo, Dasypus novemcinctus; 125 000 doses can be prepared from one animal. In addition, recent studies on the biochemical activities of these organisms may provide the knowledge required to allow cultivation on a laboratory medium. Eventually it may be possible to produce a combined leprosy:tuberculosis vaccine for use in those parts of the world where both diseases are prevalent.
PY - 1984 SP - 238 EP - 48 T2 - Vaccine TI - Leprosy--in pursuit of a vaccine. VL - 2 SN - 0264-410X ER -